Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $300K | — | $0.00 |
| Operating income | -$27.9M | — | -$21.9M |
| Operating margin | -9314.0% | — | — |
| Net income | -$36.6M | — | -$25.1M |
| Net margin | -12196.7% | — | — |
| EPS (diluted) | -$48.16 | — | -$1.51 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$25.7M | — | -$19.0M |
| Capital expenditures | $333K | — | $374K |
| Free cash flow | -$26.0M | — | -$19.4M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $1.38M | $20.6M | $17.1M |
| Total assets | $6.83M | $48.4M | $43.3M |
| Total liabilities | $47.4M | $28.5M | $30.9M |
| Long-term debt | $38.3M | $17.2M | $21.0M |
| Shareholders' equity | -$132M | -$148M | $12.4M |
| Retained earnings | -$134M | -$70.6M | -$95.6M |
| Shares (wtd avg diluted) | 760K | 780K | 16.6M |
Every figure is extracted from Adagio Medical Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.